TCR-T013

TCR-T013 is a T-cell receptor engineered T-cell (TCR-T) therapy being developed by Protheragen for the treatment of Epstein-Barr Virus (EBV)-associated cancers. The therapy involves engineering a patient's T cells to express a specific T-cell receptor that recognizes EBV antigens presented on the surface of tumor cells. By targeting EBV-infected malignant cells, TCR-T013 aims to provide a precise immunotherapeutic approach for EBV-related malignancies, such as nasopharyngeal carcinoma and certain lymphomas. It is currently in the discovery phase of development and is listed as an available project for licensing or collaboration.